Letters by company

Pd-Rx Pharmaceutical

1 letter discussing PDRX. Everything written about it on this site is on its ticker page.

Cedar Creek Partners Cedar Creek Partners 2026 Second Quarter Results Cedar Creek Partners increased expert-market exposure while building positions in companies affected by SEC Rule 15c2-11, arguing that trading restrictions create mispricings. It detailed cash-backed Harbor Diversified, Exco’s reserve development, PHI tender concerns, Solitron’s strategic review, Queen City’s ranch sale and cheaply valued community banks. Q2 ‘26 ENDI $125MEXCE $1.2BHRBR $129M